Catching Up with Guardant CEO Helmy Eltoukhy

article image

As evidence accumulates that liquid biopsy is effective in diagnosing and treating cancer patients, Guardant Health CEO Helmy Eltoukhy reflects on its rapidly evolving role in precision oncology and barriers to adoption.

The recent, virtual annual meeting of the American Society of Clinical Oncology, held May 29-May 31, highlighted the status of clinical data supporting liquid biopsy testing’s use in mainstream oncology care. Companies, led by Guardant Health Inc., are aiming to replace tissue-based genotyping with blood-based genotyping in a variety of indications. The technology is already gaining ground as an effective tool in therapy selection and clinical trial enrollment, as evidenced by the growing interest in Guardant’s Guardant360.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: